{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:13:58Z","timestamp":1778753638586,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07005-0","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:18:53Z","timestamp":1777691933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hematologic and molecular response to ropeginterferon alfa-2b in patients with polycythemia vera: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"105","author":[{"given":"Ammar","family":"Elgadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Wagealla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tibyan","family":"Noorallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayan","family":"Esmail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shafee S.","family":"Almahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"7005_CR1","doi-asserted-by":"crossref","unstructured":"Gou P, Zhang W, Giraudier S (2022) Insights into the potential mechanisms of JAK2V617F somatic mutation contributing distinct phenotypes in myeloproliferative neoplasms. Int J Mole Sci [Internet] 23(3):1013. [cited 2025 Apr 8]. Available from: https:\/\/www.mdpi.com\/1422-0067\/23\/3\/1013","DOI":"10.3390\/ijms23031013"},{"key":"7005_CR2","doi-asserted-by":"publisher","unstructured":"Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK et al (2015) Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F. JCO [Internet] 33(33):3953\u201360. [cited 2025 Apr 8]. Available from: https:\/\/doi.org\/10.1200\/JCO.2015.61.6474","DOI":"10.1200\/JCO.2015.61.6474"},{"key":"7005_CR3","doi-asserted-by":"publisher","unstructured":"Griesshammer M, Kiladjian JJ, Besses C (2019) Thromboembolic events in polycythemia vera. Ann Hematol [Internet] 98(5):1071\u201382. [cited 2025 Apr 8]. Available from: https:\/\/doi.org\/10.1007\/s00277-019-03625-x","DOI":"10.1007\/s00277-019-03625-x"},{"issue":"5","key":"7005_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.6004\/jadpro.2023.14.5.5","volume":"14","author":"M Waggoner","year":"2023","unstructured":"Waggoner M (2023) Polycythemia vera: thinking beyond the hematocrit. J Adv Practitioner Oncol 14(5):405","journal-title":"J Adv Practitioner Oncol"},{"issue":"1","key":"7005_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3324\/haematol.2016.152769","volume":"102","author":"A Alvarez-Larr\u00e1n","year":"2017","unstructured":"Alvarez-Larr\u00e1n A, P\u00e9rez-Encinas M, Ferrer-Mar\u00edn F, Hern\u00e1ndez-Boluda JC, Ram\u00edrez MJ, Mart\u00ednez-L\u00f3pez J et al (2017) Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica 102(1):103\u2013109","journal-title":"Haematologica"},{"key":"7005_CR6","doi-asserted-by":"crossref","unstructured":"Tefferi A, Vannucchi AM, Barbui T (2018) Polycythemia vera treatment algorithm 2018. Blood Cancer J [Internet] 8(1):1\u20137. [cited 2025 Apr 9]. Available from: https:\/\/www.nature.com\/articles\/s41408-017-0042-7","DOI":"10.1038\/s41408-017-0042-7"},{"key":"7005_CR7","doi-asserted-by":"crossref","unstructured":"Nazha A, Khoury JD, Verstovsek S, Daver N (2016) Second line therapies in polycythemia vera: what is the optimal strategy after hydroxyurea failure? Crit Rev Oncol\/Hematol [Internet] 105:112\u20137. [cited 2025 Apr 9]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1040842816301469","DOI":"10.1016\/j.critrevonc.2016.06.013"},{"key":"7005_CR8","doi-asserted-by":"publisher","unstructured":"Demuynck T, Verhoef G, Delforge M, Vandenberghe P, Devos T (2019) Polycythemia vera and hydroxyurea resistance\/intolerance: a monocentric retrospective analysis. Ann Hematol [Internet] 98(6):1421\u20136. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1007\/s00277-019-03654-6","DOI":"10.1007\/s00277-019-03654-6"},{"key":"7005_CR9","doi-asserted-by":"publisher","unstructured":"Kiladjian JJ, Guglielmelli P, Griesshammer M, Saydam G, Masszi T, Durrant S et al (2018) Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies. Ann Hematol [Internet] 97(4):617\u201327. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1007\/s00277-017-3225-1","DOI":"10.1007\/s00277-017-3225-1"},{"key":"7005_CR10","doi-asserted-by":"publisher","unstructured":"Kirito K, Sugimoto Y, Gotoh A, Takenaka K, Ichii M, Inano T et al (2024) Long-term safety and efficacy of ropeginterferon alfa-2b in Japanese patients with polycythemia vera. Int J Hematol [Internet] 120(6):675\u201383. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1007\/s12185-024-03846-5","DOI":"10.1007\/s12185-024-03846-5"},{"key":"7005_CR11","doi-asserted-by":"crossref","unstructured":"Verger E, Soret-Dulphy J, Maslah N, Roy L, Rey J, Ghrieb Z et al (2018) Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo. Blood Cancer J [Internet] 8(10):1\u20136. [cited 2025 Apr 9]. Available from: https:\/\/www.nature.com\/articles\/s41408-018-0133-0","DOI":"10.1038\/s41408-018-0133-0"},{"key":"7005_CR12","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M et al (2020) Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol [Internet] 7(3):e196\u2013208. [cited 2025 Apr 9]. Available from: https:\/\/www.thelancet.com\/journals\/lanhae\/article\/PIIS2352-3026-19-30236-4\/abstract"},{"key":"7005_CR13","doi-asserted-by":"publisher","unstructured":"Palandri F, Branzanti F, Venturi M, Dedola A, Fontana G, Loffredo M et al (2024) Real-life use of ropeg-interferon \u03b12b in polycythemia vera: patient selection and clinical outcomes. Ann Hematol [Internet] 103(7):2347\u201354. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1007\/s00277-024-05809-6","DOI":"10.1007\/s00277-024-05809-6"},{"key":"7005_CR14","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet] 372:n71. [cited 2025 Apr 9]. Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"7005_CR15","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919","journal-title":"BMJ"},{"key":"7005_CR16","doi-asserted-by":"publisher","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol [Internet] 5(1):13. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1186\/1471-2288-5-13","DOI":"10.1186\/1471-2288-5-13"},{"key":"7005_CR17","doi-asserted-by":"crossref","unstructured":"Suo SS, Fu RF, Qin A, Shao ZH, Bai J, Chen SN et al (2024) Effective management of polycythemia vera with ropeginterferon Alfa-2b treatment. J Hematol [Internet] 13(1\u20132):12\u201322. [cited 2025 Apr 9]. Available from: https:\/\/www.thejh.org\/index.php\/jh\/article\/view\/1245","DOI":"10.14740\/jh1245"},{"issue":"6","key":"7005_CR18","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1111\/bjh.19846","volume":"205","author":"S Suo","year":"2024","unstructured":"Suo S, Fu RF, Qin A, Shao Z, Bai J, Zhou H et al (2024) Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b. Br J Haematol 205(6):2510","journal-title":"Br J Haematol"},{"key":"7005_CR19","doi-asserted-by":"publisher","unstructured":"Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P et al (2023) Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Ann Hematol [Internet] 102(2):349\u201358. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1007\/s00277-022-05080-7","DOI":"10.1007\/s00277-022-05080-7"},{"issue":"2","key":"7005_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T et al (2022) Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol 116(2):215\u2013227","journal-title":"Int J Hematol"},{"key":"7005_CR21","doi-asserted-by":"publisher","unstructured":"Jin J, Zhang L, Qin A, Wu D, Shao Z, Bai J et al (2023) A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Exp Hematol Oncol [Internet] 12(1):55. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1186\/s40164-023-00415-0","DOI":"10.1186\/s40164-023-00415-0"},{"key":"7005_CR22","doi-asserted-by":"publisher","unstructured":"Yacoub A, Mascarenhas J, Kosiorek H, Prchal JT, Berenzon D, Baer MR et al (2019) Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood [Internet] 134(18):1498\u2013509. Oct 31 [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1182\/blood.2019000428","DOI":"10.1182\/blood.2019000428"},{"key":"7005_CR23","doi-asserted-by":"publisher","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA et al (2015) Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood [Internet] 126(15):1762\u20139. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1182\/blood-2015-04-637280","DOI":"10.1182\/blood-2015-04-637280"},{"key":"7005_CR24","doi-asserted-by":"publisher","unstructured":"Barbui T, Vannucchi AM, Stefano VD, Carobbio A, Ghirardi A, Carioli G et al (2023) Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. NEJM Evidence [Internet]. [cited 2025 Apr 9]; Available from: https:\/\/doi.org\/10.1056\/EVIDoa2200335","DOI":"10.1056\/EVIDoa2200335"},{"key":"7005_CR25","doi-asserted-by":"crossref","unstructured":"Yoon SY, Kim SY (2023) Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms. Korean J Intern Med [Internet] 38(6):810\u20137. [cited 2025 Apr 9]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC10636537\/","DOI":"10.3904\/kjim.2023.333"},{"key":"7005_CR26","doi-asserted-by":"publisher","unstructured":"Yoon SY, Lee SE (2024) Treatment with ropeginterferon alfa-2b in patients with hydroxyurea resistant or intolerant polycythemia vera in South Korea: one-year results from a phase 2 study. Blood Res [Internet] 59(1):23. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1007\/s44313-024-00026-6","DOI":"10.1007\/s44313-024-00026-6"},{"key":"7005_CR27","doi-asserted-by":"publisher","unstructured":"Yacoub A, Abu-Zeinah G, Qin A, Shih WJ, Da\u2019na W, Tashi T et al (2024) Paradigm-PV: A global, randomized, multicenter, two-arm phase IV study to assess the efficacy and safety of ropeginterferon Alfa-2b in low- and high-risk patients with polycythemia vera. Blood [Internet] 144(Supplement 1):6626. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1182\/blood-2024-199337","DOI":"10.1182\/blood-2024-199337"},{"key":"7005_CR28","doi-asserted-by":"publisher","unstructured":"Lee JY, Lee SE, Yoon SS, Yang DH, Sohn SK, Yoon SY et al (2024) Ropeginterferon in Low-Risk Patients with Polycythemia Vera. Blood [Internet] 144(Supplement 1):1799. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1182\/blood-2024-202345","DOI":"10.1182\/blood-2024-202345"},{"key":"7005_CR29","doi-asserted-by":"crossref","unstructured":"Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ et al (2011) JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res [Internet] 35(2):177\u201382. [cited 2025 Apr 9]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3626091\/","DOI":"10.1016\/j.leukres.2010.06.017"},{"key":"7005_CR30","doi-asserted-by":"publisher","unstructured":"Silver RT, Vandris K, Wang YL, Christos PJ, Adriano F, Jones AV et al (2007) JAK2V617F mutational load in patients with polycythemia vera (PV) measured by peripheral blood DNA is associated with disease severity. Blood [Internet] 110(11):2530. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1182\/blood.V110.11.2530.2530","DOI":"10.1182\/blood.V110.11.2530.2530"},{"issue":"9","key":"7005_CR31","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V et al (2007) Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 21(9):1952\u20131959","journal-title":"Leukemia"},{"key":"7005_CR32","doi-asserted-by":"publisher","unstructured":"Cacciola E, Cipolla A, Di Francesco E, Seria E, Torre M, Cacciola RR (2013) Effect Of Heterozygous JAK2 V617F On Thrombotic Risk In Patients With Polycythemia Vera: Measuring The Uncertain. Blood [Internet] 122(21):5251. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1182\/blood.V122.21.5251.5251","DOI":"10.1182\/blood.V122.21.5251.5251"},{"key":"7005_CR33","doi-asserted-by":"publisher","unstructured":"Shikhbabaeva D, Shuvaev V, Golovchenko R, Udaleva V, Fominykh M, Zotova II et al (2016) Influence of JAK2V617F allele burden on hematological response in the treatment of polycythemia vera. Blood [Internet] 128(22):547. [cited 2025 Apr 9]5. Available from: https:\/\/doi.org\/10.1182\/blood.V128.22.5475.5475","DOI":"10.1182\/blood.V128.22.5475.5475"},{"key":"7005_CR34","doi-asserted-by":"publisher","unstructured":"Skov V, Dam MJ, Pedersen RK, Andersen M, Knudsen TA, Sajid Z et al (2019) Superiority of IFN Versus HU using a novel biomarker-based tool for assessment of disease burden in MPNs. Blood [Internet] 134(Supplement_1):2972. [cited 2025 Apr 9]. Available from: https:\/\/doi.org\/10.1182\/blood-2019-126819","DOI":"10.1182\/blood-2019-126819"},{"key":"7005_CR35","doi-asserted-by":"crossref","unstructured":"Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Santos FD et al (2008) Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica [Internet] 93(11):1723\u20137. [cited 2025 Apr 9]. Available from: https:\/\/haematologica.org\/article\/view\/5078","DOI":"10.3324\/haematol.13081"},{"key":"7005_CR36","doi-asserted-by":"crossref","unstructured":"Zalcberg IR, Ayres-Silva J, Mello de Azevedo A, Solza C, Daumas A, Bonamino M (2011) Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden. Haematologica [Internet] 96(3):e18\u201320. [cited 2025 Apr 9]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3046289\/","DOI":"10.3324\/haematol.2010.037846"},{"key":"7005_CR37","doi-asserted-by":"crossref","unstructured":"Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F et al (2009) Changes of JAK2 V617F Allele Burden Over Time in Patients with Polycythemia Vera or Essential Thrombocythemia: A Retrospective Study of 172 Patients. Blood [Internet] 114(22):1892. [cited 2025 Apr 9]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497119547036","DOI":"10.1182\/blood.V114.22.1892.1892"},{"key":"7005_CR38","doi-asserted-by":"crossref","unstructured":"Tashi T, Swierczek S, Kim SJ, Salama ME, Song J, Heikal N et al (2018) Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses. Leukemia [Internet] 32(8):1830\u20133. [cited 2025 Apr 9]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6552660\/","DOI":"10.1038\/s41375-018-0080-6"},{"key":"7005_CR39","doi-asserted-by":"crossref","unstructured":"Quint\u00e1s-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL et al (2013) Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon \u03b1-2a. Blood [Internet] 122(6):893\u2013901. [cited 2025 Apr 9]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3739035\/","DOI":"10.1182\/blood-2012-07-442012"},{"key":"7005_CR40","doi-asserted-by":"crossref","unstructured":"Swierczek S, Verstovsek S, Agarwal A, Manshouri T, Hickman K, Prchal JT (2010) Pegylated Interferon-Alfa-2a In Clinical Responders Often Decreases JAK2 V617F Allelic Burden and\/or Reverses Clonal Hematopoiesis, but These Are Not Always Parallel In PV and ET Females. Blood [Internet] 116(21):1990. [cited 2025 Apr 9]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497119440585","DOI":"10.1182\/blood.V116.21.1990.1990"},{"key":"7005_CR41","doi-asserted-by":"crossref","unstructured":"Parsegov B, Namanny H, Campbell M, Zhang Y, Yan F, Christiansen M et al (2024) Quality of life evaluation for patients on ropeginterferon Alpha-2b versus other best available therapies. Blood [Internet] 144:1791. [cited 2025 Apr 9]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497124045385","DOI":"10.1182\/blood-2024-204440"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07005-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07005-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07005-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:22:57Z","timestamp":1778750577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07005-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["7005"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07005-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"9 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to publish declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Participants\u2019 consent"}},{"value":"No original data was created for this systematic review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"During the preparation of this work, the authors used ChatGPT to paraphrase sentences and to conduct grammar correction. After using this tool\/service, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}}],"article-number":"283"}}